Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of MVA85A in Latent TB
NCT02532036Phase 1Terminated
- Sponsor
- University of Oxford
- Start
- Sep 2015
- Primary completion
- Oct 2018
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MVA85A in Tuberculosis (TB) (3 arms), sponsored by University of Oxford. Primary endpoint: Adverse Events at Day 168. Started Sep 2015; status: terminated.
02
Drugs
MVA85A
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT02532036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02532036.